Prostaglandin J2 (PGJ2) is primarily studied for its role in cellular signaling and its potential therapeutic applications. It is known to induce cell differentiation and apoptosis, making it a subject of interest in cancer research. PGJ2 has been shown to inhibit the growth of certain cancer cells by activating pathways that lead to programmed cell death. Additionally, it is involved in anti-inflammatory processes, as it can suppress the activation of NF-kB, a key regulator of inflammation. This property is being explored in the context of inflammatory diseases, such as arthritis and neurodegenerative disorders. PGJ2 also plays a role in metabolic regulation, particularly in lipid metabolism, and has been investigated for its effects on insulin sensitivity and adipogenesis. Its ability to modulate these diverse biological processes highlights its potential as a target for drug development in various medical fields.